Shares of biotech micro-cap Cyclacel Pharmaceuticals have doubled in price in the past 10 days. Call it the Lloyd Christmas effect.
Acquiring Medivation will strengthen Pfizer's oncology franchise, which has lost ground in recent years to some Big Pharma competitors.
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
The cancer immunotherapy company's cash position has plunged to the point where it may no longer be capable of paying its operating expenses.